文献速递皮肤肿瘤

激活素A维持黑色素瘤相关巨噬细胞的转移表型并作为预后标志物

Activin A Sustains the Metastatic Phenotype of Tumor-Associated Macrophages and Is a Prognostic Marker in Human Cutaneous Melanoma.
PubMed 文献 · J Invest Dermatol · 2021-09-06

该研究通过Quantibody微阵列和RNA测序筛选黑色素瘤与巨噬细胞相互作用中分泌的生物标志物,发现激活素A在肿瘤相关巨噬细胞(TAM)促肿瘤和免疫抑制功能中起关键中介作用。阻断激活素可减少部分肿瘤维持基因上调并阻止促肿瘤功能获得,促进人淋巴细胞排斥黑色素瘤异种移植瘤。两独立原发皮肤黑色素瘤队列显示激活素A在预后较差患者的TAM和黑色素瘤细胞中富集,构成新的独立预后标志物。

要点

  • 激活素A是黑色素瘤细胞与单核/巨噬细胞交互作用的关键中介分子。
  • 阻断激活素可减少TAM促肿瘤基因表达并促进肿瘤排斥。
  • 激活素A在预后较差患者的TAM和黑色素瘤细胞中富集,为独立预后标志物。

核心结论

  • 激活素A是TAM促肿瘤和免疫抑制功能的关键中介,具有作为疾病生物标志物和免疫治疗靶点的潜力。

研究设计与样本

  • 使用Quantibody微阵列和RNA测序筛选黑色素瘤-巨噬细胞相互作用中分泌的生物标志物。
  • 在异种移植小鼠模型中验证激活素阻断对肿瘤排斥的影响。
  • 筛选两个独立的原发皮肤黑色素瘤标本集合评估激活素A的预后价值。

主要发现

  • 激活素A在黑色素瘤细胞与单核/巨噬细胞交互中上调肿瘤维持基因并促进TAM的促侵袭和免疫抑制功能。
  • 阻断激活素减少部分肿瘤维持基因上调并阻止促肿瘤功能获得,促进人淋巴细胞介导的黑色素瘤排斥。
  • 激活素A在预后较差患者的TAM和黑色素瘤细胞中富集,为新的独立预后标志物。

临床怎么用

  • 激活素A可作为皮肤黑色素瘤的预后生物标志物。
  • 靶向激活素A可能成为黑色素瘤免疫治疗的新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumor cells attract and dynamically interact with monocytes/macrophages to subvert their differentiation into tumor-associated macrophages (TAMs), which mainly promote immune suppression and neoplastic progression, but the pathways and microenvironmental cues governing their protumoral deviation are not completely understood. To identify the molecular pathways responsible for TAM differentiation, we screened the biomarkers secreted during melanoma‒macrophage interactions using Quantibody microarrays and RNA sequencing of macrophages. We found that activin A, a member of the transforming GF family, plays an instrumental role in the cross-talk between melanoma cells and monocytes/macrophages, which results in the upregulation of distinct tumor-sustaining genes and the achievement of proinvasive and immunosuppressive functions of TAMs. Blockade of activin reduces the upregulation of part of these genes and prevents the acquisition of protumoral functions, facilitating human melanoma rejection by transferred human lymphocytes in a xenograft mouse model. Remarkably, screening of two independent cutaneous primary melanoma collections showed that activin A is enriched in TAMs and melanoma cells from patients with worse outcomes and constitutes a new and independent prognostic marker. Thus, we identify activin A as a key intermediary in the protumoral and immunosuppressive functions of TAMs, with significant potential as a disease biomarker as well as an immunotherapeutic target.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Gutiérrez-Seijo A, García-Martínez E, Barrio-Alonso C, et al. Activin A Sustains the Metastatic Phenotype of Tumor-Associated Macrophages and Is a Prognostic Marker in Human Cutaneous Melanoma. J Invest Dermatol. 2021. PMID: 34499901. doi:10.1016/j.jid.2021.07.179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。